Virax Biolabs Group has reached an agreement for the supply of an Avian Influenza A Virus (AIV) real-time PCR test kit in the European Union (EU) region, or CE mark-accepting markets.
The test kit is intended for the identification and differentiation of ribonucleic acid from AIV and its H5, H7 and H9 subtypes. The test also covers the H5N1 strain, which is prevalent in Europe.
Designed for use in laboratory settings, the PCR test kit will enable healthcare professionals to precisely detect AIV infections.
According to the company, the specialised diagnostic kit also serves as a valuable initial screening test for individuals who were exposed to AIV-infected livestock or high-risk environments.
Virax CEO and board of directors chairman James Foster said: “We continue to expand our ViraxClear distribution platform to bring test solutions to a widening range of viral threats.
“With a real-time PCR test kit poised to accurately and reliably detect AIV, including the deadly H5N1 strain, we expect to facilitate rapid and potentially life-saving interventions, especially in vulnerable jurisdictions.”
AIV infections in humans have occurred in several countries as a result of exposure to infected poultry or virus-contaminated environments.
Six main hemagglutinin subtypes of bird flu viruses cause mild-to-severe illness, with a wide range of symptoms and complications in infected people.
These subtypes consist of the H3, H5, H6, H7, H9 and H10 viruses, of which the H5N1 and H7N9 viruses are responsible for most infections in humans.
Last month, Virax received a purchase order from Cosmos Health for the launch and marketing of its Covid-19 and Influenza A+B Antigen Combo Rapid detection kits.
Virax Biolabs is involved in the prevention, detection and diagnosis of viral diseases with a focus on the area of immunology.